Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewL-755,507
Discontinued Product
2197 has been discontinued.
View all Adrenergic β<sub>3</sub> Receptors products.
说明： Very potent and selective β3 partial agonist
化学名： 4-[[(Hexylamino)carbonyl]amino]-N-[4-[2-[[(2S)-2-hydroxy-3-(4-hydroxyphenoxy)propyl]amino]ethyl]phenyl]-benzenesulfonamide
纯度： ≥98% (HPLC)
生物活性 for L-755,507
L-755,507 is a potent β3-adrenergic receptor partial agonist > 1000-fold selective over β1- and β2-adrenoceptors (EC50 values are 0.43, 580 and > 10000 nM for activation of cloned human β3-, β1- and β2-adrenoceptors respectively). Stimulates lipolysis in rhesus adipocytes in vitro (EC50 = 3.9 nM). Enhances CRISPR-mediated homology-directed repair (HDR) efficiency 2-3-fold for large fragments and ~9-fold for point mutations, in human induced pluripotent stem cells (iPSCs).
化合物库 for L-755,507
L-755,507 is also offered as part of the Tocriscreen 2.0 Max. 了解 Tocris 化合物库的更多信息。
技术数据 for L-755,507
| 分子量 | 584.73 |
| 公式 | C30H40N4O6S |
| 储存 | Store at +4°C |
| 纯度 | ≥98% (HPLC) |
| CAS Number | 159182-43-1 |
| PubChem ID | 9829836 |
| InChI Key | NYYJKMXNVNFOFQ-MHZLTWQESA-N |
| Smiles | O=S(C1=CC=C(NC(NCCCCCC)=O)C=C1)(NC2=CC=C(CCNC[C@H](O)COC3=CC=C(O)C=C3)C=C2)=O |
上方提供的技术数据仅供参考。批次相关数据请参见分析证书。
Tocris products are intended for laboratory research use only, unless stated otherwise.
产品说明书 for L-755,507
参考文献 for L-755,507
参考文献是支持产品生物活性的出版物。
Parmee et al (1998) Discovery of L-755,507: a subnanomolar human β3 adrenergic receptor agonist. Bioorg.Med.Chem.Lett. 8 1107 PMID: 9871717
Fisher et al (1998) A selective human β3 adrenergic receptor agonist increases metabolic rate in rhesus monkeys. J.Clin.Invest. 101 2387 PMID: 9616210
Yu et al (2015) Small molecules enhance CRISPR genome editing in pluripotent stem cells. Cell Stem Cell 16 142 PMID: 25658371
按标靶查看相关产品
按产品操作查看相关产品
关键词: L-755,507, L-755,507 supplier, potent, selective, β3, beta3, partial, agonists, adrenergic, receptors, adrenoceptors, L755507, CRISPR, Cas9, HDR, NHEJ, homology, directed, repair, nonhomologous, end, joining, hematopoietic, haematopoietic, stem, cells, HSC, Adrenergic, Beta-3, Receptors, Reagents, Hematopoietic, Stem, Cells, 2197, Tocris Bioscience
6 篇 L-755,507 的引用文献
引用文献是使用了 Tocris 产品的出版物。 L-755,507 的部分引用包括：
Afeli et al (2012) Do β3-adrenergic receptors play a role in guinea pig detrusor smooth muscle excitability and contractility?. Am J Physiol Renal Physiol 302 F251 PMID: 21993887
Coan et al (2009) Promiscuous aggregate-based inhibitors promote enzyme unfolding. J Med Chem 52 2067 PMID: 19281222
Riesenberg and Maricic (2018) Targeting repair pathways with small molecules increases precise genome editing in pluripotent stem cells. Nat Commun 9 2164 PMID: 29867139
Kornete et al (2018) Highly Efficient and Versatile Plasmid-Based Gene Editing in Primary T Cells. J Immunol 200 2489 PMID: 29445007
Pinder et al (2015) Nuclear domain 'knock-in' screen for the evaluation and identification of small molecule enhancers of CRISPR-based genome editing. Nucleic Acids Res 43 9379 PMID: 26429972
Coan and Shoichet (2008) Stoichiometry and physical chemistry of promiscuous aggregate-based inhibitors. J Am Chem Soc 130 9606 PMID: 18588298
L-755,507 的评论
目前没有该产品的评论。 Be the first to review L-755,507 and earn rewards!
Have you used L-755,507?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
该领域的文献
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*请注意，Tocris 仅会向正规科研企业/机构地址发送文献。
Depression Poster
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.